Background/aim: With advances in anti-HER2 treatment and improved prognoses of HER2-positive breast cancer, the American Society of Clinical Oncology and the American Society of Pathologists (ASCO/CAP) have revised the HER2 diagnostic guidelines several times. We examined how to respond clinically to the revisions of the interpretation of the immunohistochemistry (IHC) method.
Patients And Methods: We re-evaluated 254 patients diagnosed as HER2 IHC equivocal, who underwent fluorescence in situ hybridization (FISH) before and after the IHC diagnostic criteria update in 2013.
Results: Twenty of 131 (15.3%) IHC equivocal cases by the ASCO/CAP 2007 guideline were IHC score 3+ and one of 20 (0.76%) was negative for FISH. Five of 123 (4.1%) IHC equivocal cases by the ASCO/CAP 2013 guideline were negative for IHC as per the 2007 guideline and four were positive for FISH.
Conclusion: After revision of the ASCO/CAP 2013 guideline, 3.3% of HER2-negative cases before the revision should have received anti-HER2 treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.15217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute.
PLoS One
January 2025
Department of Clinical Support Services, Division of Laboratory and Pathology Medicine, Uganda Cancer Institute, Kampala, Uganda.
Article Synopsis
- This study focused on detecting Estrogen Receptor (ER), Progesterone Receptor (PR), and HER-2 in breast cancer to help categorize the disease and guide treatment choices.
- Researchers compared two preservation methods for breast tissue samples: traditional formalin fixation and RNAlater, utilizing Immunohistochemistry (IHC) and Quantitative Polymerase Chain Reaction (qPCR) for analysis.
- Findings revealed that ER and PR were positive in 60% of samples, while HER-2 was positive in only 25%, with no significant statistical difference between the results from the two preservation methods.
Analytical Validation and Performance Evaluation of Amplicon-Based Next-Generation Sequencing Assays for Detecting and Other Gene Amplifications in Solid Tumors.
Cancers (Basel)
November 2024
Precision Diagnostics and Therapeutics Program, Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Background: Targeted next-generation sequencing (NGS) panels are increasingly being utilized to identify actionable gene amplifications (copy number > 4) among solid tumors.
Methods: This study validated the analytical performance of two amplicon-based NGS assays, the Oncomine Comprehensive Panel (OCAv3) and the Oncomine Focus Assay (OFA), for detecting gene amplification in formalin-fixed paraffin-embedded (FFPE) tumors of varying cellularity. OCAv3 was assessed for amplification detection in 756 FFPE samples comprising various tumor types.
The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions.
Obstet Gynecol Sci
September 2024
Department of General Surgery, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Immunohistochemistry (IHC) has become an indispensable tool in routine gynecological pathology, particularly with the advancements in molecular understanding and histological classification of gynecological cancers. This evolution has led to new immunostainings for diagnostic and classification purposes. This review describes the diagnostic utility of IHC in gynecological neoplasms, drawing insights from literature reviews, personal experiences, and research findings.
View Article and Find Full Text PDFSimultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas.
Head Neck Pathol
August 2024
Department of Pathology, University of Turku, Turku University Hospital, D5020, Medisiina D, 5. floor Kiinamyllynkatu 10, Turku, FIN-20520, Finland.
Article Synopsis
- The study aimed to evaluate the effectiveness of simultaneous staining for p16 and p53 proteins in categorizing head and neck squamous cell carcinomas (HNSCC) as either HPV-associated or HPV-independent.
- Researchers stained 31 HNSCC samples for p16 and p53, and used advanced sequencing methods to analyze mutations and HPV presence in some cases.
- Results showed that most tumors (28 out of 31) could be classified simply based on the staining patterns, with most HPV-A tumors having p16 positivity and wildtype p53, while HPV-I tumors showed p16 negativity and abnormal p53 patterns.
Detection of RAS p.Q61R by Immunohistochemistry in Practice: A Clinicopathologic Study of 217 Thyroid Nodules with Molecular Correlates.
Endocr Pathol
September 2024
Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Warren 219, Boston, MA, 02114, USA.
RAS p.Q61R is the most prevalent hot-spot mutation in RAS and RAS-like mutated thyroid nodules. A few studies evaluated RAS p.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!